Bluebird’s Zynteglo Shows Long-Term Efficacy And Safety Amid US Commercialization Push

 
• By Alaric DeArment
  
Bluebird presented long-term data for Zynteglo at ASH 2022 • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Gene Therapies

More from Advanced Therapies